Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26405752 | 0.84 | LMNA (0.44) | CYP17A1AAK1RXFP1MAP4K4LMNA | |
| SCHEMBL26405735 | 0.83 | AAK1 (0.41) | AAK1MAP4K4 | |
| SCHEMBL29952152 | 0.81 | CYP17A1 (0.42) | CYP17A1AAK1BRAFRXFP1KCNQ4 | |
| SCHEMBL6578723 | 0.81 | CYP17A1 (0.44) | CYP17A1AAK1BRAFRXFP1MAP4K4 | |
| SCHEMBL29448813 | 0.81 | CYP17A1 (0.44) | CYP17A1AAK1BRAFRXFP1MAP4K4 | |
| SCHEMBL197226 | 0.80 | AAK1 (0.43) | CYP17A1AAK1BRAFRXFP1MAP4K4 | |
| SCHEMBL29174184 | 0.80 | MAPT (0.42) | CYP17A1BRAFRXFP1 | |
| SCHEMBL26128015 | 0.78 | ERN1 (0.37) | CA12CA1CA9HDAC1HDAC2 | |
| SCHEMBL12519275 | 0.78 | AAK1 (0.44) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL14725520 | 0.78 | CYP17A1 (0.48) | CYP17A1AAK1BRAFRXFP1KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| CN-119948062-A | NAPI 2B-targeted antibody-drug conjugates and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025081282-A1 | ANTI-NAPI2B ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-04-24 | — | — | WO | disclosed |
| EP-4499698-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-02-05 | — | — | EP | disclosed |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| CN-118922447-A | Folate receptor alpha-targeting antibody-drug conjugates and methods of use | 酵活英属哥伦比亚有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2024-08-15 | — | — | US | disclosed |
| WO-2024082055-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| CN-117715914-A | Camptothecin analogs, conjugates, and methods of use | 酵活英属哥伦比亚有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | TOP2A, TOP1, TOP2B | CYP17A1 437/4885AAK1 3794/4885BRAF 1148/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | CYP17A1 561/4885AAK1 2322/4885BRAF 931/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | CYP17A1 561/4885AAK1 2322/4885BRAF 931/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | CYP17A1 2169/4885AAK1 3302/4885BRAF 3706/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | CYP17A1 2365/4885AAK1 4117/4885BRAF 4468/4885 |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | CYP17A1 561/4885AAK1 2322/4885BRAF 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.